BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 21286912)

  • 1. Three years of paediatric regulation in the European Union.
    Olski TM; Lampus SF; Gherarducci G; Saint Raymond A
    Eur J Clin Pharmacol; 2011 Mar; 67(3):245-52. PubMed ID: 21286912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paediatric investigation plans for pain: painfully slow!
    Davies EH; Ollivier CM; Saint Raymond A
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1091-7. PubMed ID: 20821198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral medicines for children in the European paediatric investigation plans.
    van Riet-Nales DA; Römkens EG; Saint-Raymond A; Kozarewicz P; Schobben AF; Egberts TC; Rademaker CM
    PLoS One; 2014; 9(6):e98348. PubMed ID: 24897509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Juvenile animal studies and pediatric drug development: a European regulatory perspective.
    Carleer J; Karres J
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):254-60. PubMed ID: 21638754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Who are the PDCO?
    Dempsey EM; Connolly K
    Eur J Pediatr; 2014 Feb; 173(2):233-5. PubMed ID: 23925423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The European Regulation on medicines for paediatric use.
    Dunne J
    Paediatr Respir Rev; 2007 Jun; 8(2):177-83. PubMed ID: 17574163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The EU paediatric regulation: still a large discrepancy between therapeutic needs and approved paediatric investigation plans.
    Wimmer S; Rascher W; McCarthy S; Neubert A
    Paediatr Drugs; 2014 Oct; 16(5):397-406. PubMed ID: 25056717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
    Rose K
    Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contributions of the European Medicines Agency and its pediatric committee to the fight against childhood leukemia.
    Rose K; Walson PD
    Risk Manag Healthc Policy; 2015; 8():185-205. PubMed ID: 26604845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee--adolescents' melanoma as a paradigm.
    Rose K; Senn S
    Pharm Stat; 2014; 13(4):211-3. PubMed ID: 24903307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usage of unpublished paediatric data.
    Saint-Raymond A; Pelle B; Zaccaria C; Sennwitz M; Branch S
    Arch Dis Child; 2016 Jan; 101(1):81-4. PubMed ID: 26543071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory environment for allergen-specific immunotherapy.
    Kaul S; May S; Lüttkopf D; Vieths S
    Allergy; 2011 Jun; 66(6):753-64. PubMed ID: 21288251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Where is industry getting it wrong? A review of quality concerns raised at Day 120 by the Committee For Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products.
    Borg JJ; Robert JL; Wade G; Aislaitner G; Pirozynski M; Abadie E; Salmonson T; Vella Bonanno P
    J Pharm Pharm Sci; 2009; 12(2):181-98. PubMed ID: 19732496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of medicines for children. Part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni.
    Rocchi F; Tomasi P
    Pharmacol Res; 2011 Sep; 64(3):169-75. PubMed ID: 21376810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The European paediatric legislation: benefits and perspectives.
    Rocchi F; Paolucci P; Ceci A; Rossi P
    Ital J Pediatr; 2010 Aug; 36():56. PubMed ID: 20716337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.